
ALT • There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM). • Supply is not expected to return to normal until at least mid-2024. • The supply issues have been caused by an increase in demand for these products for licensed and off-label indications. Actions Required MSN/2023/061 Actions for clinicians until supply issues have resolved: • GLP-1 RAs should only be prescribed for their licensed indication • Avoid initiating people with type 2 diabetes on GLP-1 RAs for the duration of the GLP1-RA national shortage. • Review the need for prescribing a GLP-1 RA agent and stop treatment if no longer required due to not achieving desired clinical effect as per NICE CG28. • Avoid switching between brands of GLP-1 RAs, including between injectable and oral forms. • Where a higher dose preparation of GLP-1 RA is not available, do not substitute by doubling up a lower dose prep

ALT A survey of more than 200 colleagues supported by legacy nurses at Norfolk and Waveney ICS found that more than 60% of colleagues felt more valued by their team, more than 80% had greater confidence in their role, more than half strongly agreed they were more likely to continue working in the NHS and over 70% of colleagues reported increased job satisfaction.

































